1.Obseration of curative effect of extracorporeal lipoprotein filter from plasma Delipid Plus therapy on acute cerebral infarction
Mingyuan LIU ; Yangtai GUAN ; Xiaojun HOU
Journal of Clinical Neurology 1997;0(06):-
Objective To explore the curative effect of extracorporeal lipoprotein filter from plasma Delipid Plus(DELP) system therapy on acute cerebral infarction(ACI). Methods 36 patients with ACI were divided into DELP group (12 cases) and control group (24 cases). All of them received basic treatment including Aspirin and Pravastatin sodium etc. The DELP group also treated by DELP therapy twice. The scores of National Institute of Health Stroke Scale (NIHSS),Barthel Index (BI) and Modified Rankin Scale (mRS),and the levels of plasma fibrinogen (Fib),blood lipid and the indexes of hemorheology were compared pre and post treatment in the two groups.Results The reduction value of NIHSS between pre and post treatment in DELP group was bigger than this in control group(P
2.Pathological damage of optic nerve in mice by the application of TACI-Ig
Lu HAN ; Hong YANG ; Mei LI ; Desheng ZHU ; Zezhi LI ; Mingyuan LIU ; Yangtai GUAN
Journal of Shanghai Jiaotong University(Medical Science) 2017;37(7):901-905
Objective·To eliminate the effects of intraperitoneal injection of transmembrane activator and calcium modulator and cyclophilin ligand interactor-Ig (TACI-Ig) on the opitc neuritis and the integrity of myelin sheath in mice.Methods·Twenty-four C57BL/6J mice were randomly divided into 4 groups,which were blank control group,saline control group,low-dose (0.4 mg/kg) TACI-Ig group and high-dose (4 mg/kg) TACI-Ig group,with 6 mice in each group.All groups were received intraperitoneal injection every other day.The saline control group received 0.2 mL saline injection in the same way,and the blank control group was not given any intervention.After 20 d of treatment,the eyeballs and optic nerve tissues were collected from each mouse under anaesthesia,embedded in paraffin and stained with hematoxylin-eosin (H-E) and Luxol fast blue (LFB),respectively.Results·H-E staining indicated that optic nerve fibers arranged closely both in blank and saline control groups and the staining of tissues was uniform.The optic nerve structure of low-dose TACI-Ig group was similar to blank and saline control groups,while in high-dose of TACI-Ig group,the infiltration of inflammatory cells was observed.The inflammatory cell infiltration scores were not significantly different in all groups (P=0.610 3).The retinal structures of all groups were clear and distinct to observe,and single ganglion cells arranged tightly with complete cell shape,visible nucleus and uniform distribution.There was no difference in the retina structure among 4 groups.LFB staining indicated that there was no significant loss of the optic nerve myelin in 4 groups by microscope observation (P=0.473 6).Conclusion·Low-dose (0.4 mg/kg) TACI-Ig injection wouldn't damage the normal structure of optic nerves and retinal ganglion cells,meanwhile high-dose (4 mg/kg) of TACI-Ig injection might cause minor infiltration of inflammatory cells into retina.
3.Preliminary observation of the results of external irradiation combined with brachytherapy for inoperable locally advanced rectal cancer
Zhipeng ZHAO ; Dan LI ; Wei GUAN ; Mingyuan HE ; Guanghui CHENG ; Ning WU
Chinese Journal of Radiation Oncology 2020;29(6):437-440
Objective:To explore the clinical efficacy and adverse reactions of the combination of external beam radiotherapy followed by three-dimensional intracavitary brachytherapy in patients with inoperable locally advanced rectal cancer.Methods:Clinical data of 11 patients with inoperable locally advanced rectal cancer, 7 male and 4 female, admitted to China-Japan Union Hospital of Jilin University from 2013 to 2015 were retrospectively analyzed. All patients received pelvic external irradiation (50 Gy in 25 fractions), followed by a three-dimensional intracavitary brachytherapy boost (15-20 Gy in 3-4 fractions, 1 fraction/week). External beam radiotherapy was used to boost the dose to the perirectal lymph nodes (60-66 Gy in 30-33 fractions). All patients received concurrent chemotherapy with Capecitabine during external beam radiotherapy. Efficacy evaluation was performed using the RECIST standard. Survival and local control rates were calculated using the Kaplan- Meier method. Early and late radiotherapy responses were assessed using the RTOG lesion grading criteria. Results:The CTV D 90% EQD 2 Gy of HDR 3D-ICBT among 11 patients was (21.3±1.60) Gy. The complete response (CR) and partial response (PR) rates were 64% and 27%, respectively, yielding an objective response rate (CR+PR) of 91%. With a median follow-up time of 36 months, the 1-, 2-, and 3-year overall survival rates were 82%, 64% and 46%, respectively. The 1-, 2-, 3-year disease-free survival rates were 64%, 45% and 27%, respectively. The 3-year local control rate was 46%. One patient presented with lung metastases after 8 months, 7 patients experienced grade 1-2 acute intestinal reactions and 5 patients developed grade 1-2 acute bladder reactions, only one patient had grade 2 myelosuppression; long-term grade 1-2 intestinal reactions occurred in 5 patients, and 1 patient had long-term grade 1-2 bladder reaction. All the radiation-induced toxicities were alleviated by medication administration. Conclusions:External beam radiotherapy followed by three-dimensional intracavitary brachytherapy can be a safe and effective surrogate in patients with inoperable locally advanced rectal cancer, which yields reliable clinical efficacy and tolerable adverse reactions.
4.Efficacy and safety of five monoclonal antibodies in preventing relapse of neuromyelitis optica spectrum disorders:network meta-analysis
Mingyuan GUAN ; Ting WANG ; Ranran DUAN ; Ying LI
China Pharmacy 2023;34(5):607-612
OBJECTIVE To indirectly compare and evaluate the efficacy and safety of rituximab, tocilizumab, eculizumab, inebilizumab and satralizumab in preventing the relapse of neuromyelitis optica spectrum disorders, so as to provide reference for clinical drug use. METHODS Retrieved from Embase, Medline, PubMed, CNKI, ClinicalTrials. gov, UMIN Clinical Trials Registry and Chinese Clinical Trial Registry, randomized controlled trials (RCTs) about five monoclonal antibodies (trial group) versus placebo or other therapeutic scheme (control group) were collected during the inception to Apr. 2022. Two reviewers independently screened literature, extracted data, and assessed the quality of included literature with Cochrane risk bias assessment tool. OpenBUGS software was used for network meta-analysis. In terms of safety, Chi-square test was performed for adverse events (AEs) in trial group and control group. RESULTS A total of 7 RCTs were included, involving 793 patients. The results of surface under the cumulative ranking curve (SUCRA) showed the order of capabilities decreasing relapse risk was: eculizumab> rituximab>inebilizumab>satralizumab; the order of capabilities reducing the annual recurrence rate was: eculizumab> satralizumab; the order of capabilities improving the progress of disability was: eculizumab>satralizumab>inebilizumab> rituximab>tocilizumab. In terms of safety, the results of χ2 test showed that there were no statistically significant differences in the risk of total AEs and serious AEs in each study between trial groups and control groups (P>0.05); the incidence of infusion reaction, nausea and vomiting in rituximab group, and that of upper respiratory tract infection in eculizumab group were significantly higher than placebo group (P<0.05). CONCLUSIONS The effect of eculizumab is more optimal in three outcomes; in terms of improving the progress of disability, eculizumab, satralizumab and inebilizumab are more effective than the other two drugs; in terms of safety, there are significant goldenmoonsp@163.com differences in some AEs with different grades and individual AEs, but it is not found that they are inconsistent with the 学。E-mail:liyingpds@126.com reported results of the existing literature and drug instructions.
5. Antimicrobial susceptibility and drug-resistance genes of Yersinia spp. of retailed poultry in 4 provinces of China
Zixin PENG ; Mingyuan ZOU ; Jin XU ; Wenying GUAN ; Ying LI ; Danru LIU ; Shuhong ZHANG ; Qiong HAO ; Shaofei YAN ; Wei WANG ; Dongmin YU ; Fengqin LI
Chinese Journal of Preventive Medicine 2018;52(4):358-363
Objective:
To monitor the antimicrobial resistance and drug-resistance genes of